Literature DB >> 18522932

Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer.

M Hickey1, C Saunders, A Partridge, N Santoro, H Joffe, V Stearns.   

Abstract

BACKGROUND: The purpose of this study was to provide practical, evidence-based guidelines for evaluating and treating common menopausal symptoms following breast cancer.
METHODS: Literature review of the causes, assessment and management of menopausal symptoms in breast cancer patients.
RESULTS: A number of nonhormonal treatments are effective in treating hot flashes. Whether pharmacological treatment is given will depend on the severity of symptoms and on patient wishes. For severe and frequent hot flashes, the best data support the use of venlafaxine, paroxetine and gabapentin in women with breast cancer. Side-effects are relatively common with all these agents. For vaginal dryness, topical estrogen treatment is the most effective but the safety of estrogens following breast cancer is not established. There are limited data on effective treatments for sexual dysfunction during menopause.
CONCLUSION: Menopausal symptoms after breast cancer should be evaluated and managed as warranted using a systematic approach and may benefit from multidisciplinary input.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18522932     DOI: 10.1093/annonc/mdn353

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  28 in total

1.  Update in new medications for primary care.

Authors:  Gerald W Smetana; Jane S Sillman
Journal:  J Gen Intern Med       Date:  2009-12-12       Impact factor: 5.128

Review 2.  Challenges in the gynecologic care of premenopausal women with breast cancer.

Authors:  Jamie N Bakkum-Gamez; Shannon K Laughlin; Jani R Jensen; Clement O Akogyeram; Sandhya Pruthi
Journal:  Mayo Clin Proc       Date:  2011-02-09       Impact factor: 7.616

Review 3.  Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations.

Authors:  Sylvain L'Espérance; Suzanne Frenette; Anne Dionne; Jean-Yves Dionne
Journal:  Support Care Cancer       Date:  2013-02-23       Impact factor: 3.603

4.  Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.

Authors:  G J van Londen; Heidi S Donovan; Ellen B Beckjord; Alexandra L Cardy; Dana H Bovbjerg; Nancy E Davidson; Jennifer Q Morse; Galen E Switzer; Irma M Verdonck-de Leeuw; Mary Amanda Dew
Journal:  Oncol Nurs Forum       Date:  2014-11-01       Impact factor: 2.172

5.  Menopausal symptoms in breast cancer survivors: management update.

Authors:  Leila Cusack; Meagan Brennan; Rodney Baber; Frances Boyle
Journal:  Br J Gen Pract       Date:  2013-01       Impact factor: 5.386

6.  Long-term chinese herbs decoction administration for management of hot flashes associated with endocrine therapy in breast cancer patients.

Authors:  Dong Xue; Hong Sun; Ping-Ping Li
Journal:  Chin J Cancer Res       Date:  2011-03       Impact factor: 5.087

7.  The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause.

Authors:  Carmel Pezaro; Paul James; Joanne McKinley; Mary Shanahan; Mary-Anne Young; Gillian Mitchell
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

8.  The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview.

Authors:  Cheryl Phua; Rodney Baber
Journal:  Drugs Aging       Date:  2018-08       Impact factor: 3.923

Review 9.  Systematic review of acupuncture to control hot flashes in cancer patients.

Authors:  M Kay Garcia; Leslie Graham-Getty; Robin Haddad; Yisheng Li; Jennifer McQuade; Richard T Lee; Michael Spano; Lorenzo Cohen
Journal:  Cancer       Date:  2015-08-17       Impact factor: 6.860

Review 10.  Breast cancer in young women and its impact on reproductive function.

Authors:  M Hickey; M Peate; C M Saunders; M Friedlander
Journal:  Hum Reprod Update       Date:  2009-01-27       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.